Aller au contenu principal
Profil bibliographique

Junfeng Jia

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

31Publications signalées
305Citations signalées
3Affiliations récentes

Les institutions déclarées

Les domaines associés

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSignaling Pathways in DiseaseLiver Disease Diagnosis and TreatmentSystemic Sclerosis and Related DiseasesSaffron Plant Research Studies

Les publications récentes

Accès ouvert 2025 review OpenAlex

Predictive Value of Machine Learning in Knee Osteoarthritis Progression: Systematic Review and Meta-Analysis

Yanwen Liu, Guangzhi Xiao, Youqun Zhang, Xinyi Wang et autres

Background: Machine learning (ML) has been investigated for its predictive value in knee osteoarthritis (KOA) progression. However, systematic evidence on the effectiveness of ML is still lacking, posing a challenge to precision prevention. Objective: This systematic review aimed to systematically assess the …

cn (code pays fourni par la source)

6 citations Journal of Medical Internet Research
Accès ouvert 2025 article OpenAlex

A Lung Ultrasound Score for Assessing Connective Tissue Disease‐Related Interstitial Lung Disease: Performance and Comparison With Computed Tomography Quantification

Ying Zhang, Linxuan Pang, Ning Guo, Wenjuan Wang et autres

BACKGROUND AND OBJECTIVE: The role of lung ultrasound's (LUS) in diagnosing and assessing connective tissue disease (CTD)-related interstitial lung disease (ILD) remains controversial. We aimed to evaluate the diagnostic performance of a quantitative LUS score and the correlations between LUS scores and …

cn (code pays fourni par la source)

1 citation Respirology
Accès ouvert 2025 article OpenAlex

Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial

Huijie Bian, Chen Liang, Zheng Zhang, Aidong Wen et autres

Meplazumab, a humanized CD147 antibody, showed favorable safety and clinical benefits in phase 1 and phase 2/3 seamless clinical studies. Further evaluation of its therapeutic efficacy in patients with severe COVID-19 is needed. In this phase 3 add-on study, we randomized patients …

cn (code pays fourni par la source)

4 citations Signal Transduction and Targeted Therapy
Accès ouvert 2024 article OpenAlex

Development of a risk prediction model for the first occurrence of thrombosis in patients with OAPS

Jie Gao, Yan Zheng, Zhuo Wang, Junfeng Jia et autres

Objectives: The aim of this study is to assess the risk factors associated with thrombotic events in obstetric antiphospholipid syndrome (OAPS) patients and to develop a predictive model specifically tailored to predict the risk of postpartum thrombosis in OAPS patients without prior …

cn (code pays fourni par la source)

5 citations Frontiers in Immunology
Accès ouvert 2023 article OpenAlex

Network pharmacology-based analysis on geniposide, a component of gardenia jasminoides, beneficial effects to alleviate LPS-induced immune stress in piglets

Zhuorui Shan, Junfeng Jia, Qiuju Wang, Yizhe Cui

Geniposide is the main medicinal component of Gardenia jasminoides, and its content is approximately 3-8% depending on its origin. Geniposide is a class of cyclic enol ether terpene glucoside compounds with strong antioxidant, free radical quenching and cancer-inhibiting activities. Many studies have …

cn (code pays fourni par la source)

9 citations International Immunopharmacology
Accès ouvert 2023 article OpenAlex

Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial

Huijie Bian, Liang Chen, Zhaohui Zheng, Xiuxuan Sun et autres

Meplazumab, a humanized CD147 antibody, has shown favourable safety and efficacy in our previous clinical studies. In DEFLECT (NCT04586153), 167 patients with severe COVID-19 were enroled and randomized to receive three dosages of meplazumab and a placebo. Meplazumab at 0.12 mg/kg, compared …

cn, us, pk, br, nz (code pays fourni par la source)

18 citations Signal Transduction and Targeted Therapy
Accès ouvert 2023 article OpenAlex

Case report: Kimura's disease with minimal degenerative glomerulopathy without eosinophil infiltration responds to mycophenolate mofetil treatment

Qing Han, Jie Han, W. T. Wang, Jie Gao et autres

Kimura's disease (KD) is a rare chronic progressive immune inflammatory disease. The etiology is unknown and manifests as a chronic inflammatory process, which is more common in young Asian men. The clinical manifestations are painless subcutaneous swelling of the head and neck …

cn (code pays fourni par la source)

8 citations Frontiers in Medicine
Accès ouvert 2023 article OpenAlex

Current situation of acute ST-segment elevation myocardial infarction in a county hospital chest pain center during an epidemic of novel coronavirus pneumonia

Feng Li, Rong Luo, Xiaoting Wang, Junfeng Jia et autres

Abstract Our object was to examine how the pre- and post-pandemic COVID-19 impacted the care of acute ST-segment elevation myocardial infarction (STEMI) patients in county hospitals. Using January 20, 2020, as the time point for the control of a unique coronavirus pneumonia …

3 citations Open Medicine
Accès ouvert 2022 article OpenAlex

Investigation and Analysis of Anxiety and Quality of Life among Systemic Lupus Erythematosus Patients in Northwestern China

Qing Wang, Junfeng Jia, Kui Zhang, Zhaohui Zheng et autres

The aim of this study was to provide targeted psychological support and effective nursing for systemic lupus erythematosus (SLE) patients. SLE is a complex, systemic autoimmune disease characterized by recurrent episodes and the involvement of multiple organs. With improvements in SLE treatment …

cn (code pays fourni par la source)

1 citation Healthcare

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.